The 7 major hepatitis D markets reached a value of US$ 665.1 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 845.3 Million by 2034, exhibiting a growth rate (CAGR) of 2.70% during 2023-2034.
The hepatitis D market has been comprehensively analyzed in this report titled "Hepatitis D Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatitis D refers to a liver infection caused by the hepatitis D virus that only develops in individuals who have already been infected with the hepatitis B virus. The disease is mainly transmitted through contact with infected blood or bodily fluids. It can produce severe symptoms and significant illnesses, which can result in lifelong liver damage and possibly death. The most common indications associated with the condition include fatigue, jaundice, abdominal pain, loss of appetite, joint pain, dark urine, pale stools, etc. Some individuals with chronic hepatitis D may not experience noticeable symptoms for an extended period, but they can still be carriers of the virus and at risk of liver damage. The diagnosis of this ailment typically involves a combination of medical history assessment, physical examination, and laboratory tests, such as blood workups and specific serologic assays. In some cases, the medical practitioner may also perform numerous imaging studies, including ultrasounds, computed tomography (CT) scans, magnetic resonance imaging (MRI), etc., to evaluate the abnormalities in the liver or assess the extent of hepatic damage.
The increasing prevalence of hepatitis B infection that promote viral replication as well as the assembly of new virions is primarily driving the hepatitis D market. In addition to this, the rising incidences of injectable drug use and unprotected sexual intercourse, which can enhance the likelihood of virus transmission, are also bolstering the market growth. Furthermore, the widespread adoption of antiviral medications, including pegylated interferon-alpha and bulevirtide, for treating the ailment is acting as another significant growth-inducing factor. These agents mainly work by inhibiting the reverse transcriptase enzyme and suppressing viral DNA replication to reduce the risk of disease worsening and liver damage in patients. Additionally, the escalating demand for lifestyle changes, which involve consuming a healthy diet and avoiding alcohol, to relieve symptoms, improve hepatic function, and maintain overall health, is also creating a positive outlook for the market. Moreover, the emerging popularity of nucleoside analogs, owing to their numerous advantages, such as lowering viral load and decreasing liver inflammation, is expected to drive the hepatitis D market in the coming years.
This report provides an exhaustive analysis of the hepatitis D market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatitis D and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatitis D market in any manner.
The hepatitis D market has been comprehensively analyzed in this report titled "Hepatitis D Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatitis D refers to a liver infection caused by the hepatitis D virus that only develops in individuals who have already been infected with the hepatitis B virus. The disease is mainly transmitted through contact with infected blood or bodily fluids. It can produce severe symptoms and significant illnesses, which can result in lifelong liver damage and possibly death. The most common indications associated with the condition include fatigue, jaundice, abdominal pain, loss of appetite, joint pain, dark urine, pale stools, etc. Some individuals with chronic hepatitis D may not experience noticeable symptoms for an extended period, but they can still be carriers of the virus and at risk of liver damage. The diagnosis of this ailment typically involves a combination of medical history assessment, physical examination, and laboratory tests, such as blood workups and specific serologic assays. In some cases, the medical practitioner may also perform numerous imaging studies, including ultrasounds, computed tomography (CT) scans, magnetic resonance imaging (MRI), etc., to evaluate the abnormalities in the liver or assess the extent of hepatic damage.
The increasing prevalence of hepatitis B infection that promote viral replication as well as the assembly of new virions is primarily driving the hepatitis D market. In addition to this, the rising incidences of injectable drug use and unprotected sexual intercourse, which can enhance the likelihood of virus transmission, are also bolstering the market growth. Furthermore, the widespread adoption of antiviral medications, including pegylated interferon-alpha and bulevirtide, for treating the ailment is acting as another significant growth-inducing factor. These agents mainly work by inhibiting the reverse transcriptase enzyme and suppressing viral DNA replication to reduce the risk of disease worsening and liver damage in patients. Additionally, the escalating demand for lifestyle changes, which involve consuming a healthy diet and avoiding alcohol, to relieve symptoms, improve hepatic function, and maintain overall health, is also creating a positive outlook for the market. Moreover, the emerging popularity of nucleoside analogs, owing to their numerous advantages, such as lowering viral load and decreasing liver inflammation, is expected to drive the hepatitis D market in the coming years.
This report provides an exhaustive analysis of the hepatitis D market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatitis D and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatitis D market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the hepatitis D market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the hepatitis D market
Competitive Landscape:
This report also provides a detailed analysis of the current hepatitis D marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the hepatitis D market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the hepatitis D market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the hepatitis D market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of hepatitis D across the seven major markets?
- What is the number of prevalent cases (2018-2034) of hepatitis D by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of hepatitis D by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with hepatitis D across the seven major markets?
- What is the size of the hepatitis D patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of hepatitis D?
- What will be the growth rate of patients across the seven major markets?
Hepatitis D: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for hepatitis D drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatitis D market?
- What are the key regulatory events related to the hepatitis D market?
- What is the structure of clinical trial landscape by status related to the hepatitis D market?
- What is the structure of clinical trial landscape by phase related to the hepatitis D market?
- What is the structure of clinical trial landscape by route of administration related to the hepatitis D market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Hepatitis D - Unmet Needs10 Hepatitis D - Key Endpoints of Treatment13. Hepatitis D - Attribute Analysis of Key Marketed and Pipeline Drugs16 Hepatitis D - Recent Events and Inputs From Key Opinion Leaders18 Hepatitis D Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Hepatitis D - Introduction
5 Hepatitis D - Disease Overview
7 Hepatitis D - Epidemiology and Patient Population
8 Hepatitis D - Treatment Algorithm, Guidelines, and Medical Practices
11 Hepatitis D - Marketed Products
12 Hepatitis D - Pipeline Drugs
14. Hepatitis D - Clinical Trial Landscape
15 Hepatitis D - Market Scenario
17 Hepatitis D Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 134 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 665.1 Million |
| Forecasted Market Value ( USD | $ 845.3 Million |
| Compound Annual Growth Rate | 2.2% |
| Regions Covered | Global |
